What's in Syntara's pipeline?

Syntara has 8 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with Syntara's portfolio?

No competitive overlap detected.

Subscribe to /feed/company/syntara.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Syntara pipeline: 1 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Drug	Generic	Phase	Class	Area
Aridol	Aridol	marketed		Other
Matching Placebo (B)	Matching Placebo (B)	phase 3
Placebo Comparator: Arm B - Control	Placebo Comparator: Arm B - Control	phase 3
Inhaled mannitol	Inhaled mannitol	phase 3	Osmotic agent / Mucoactive agent	Respiratory / Pulmonology

No regulatory actions in the last 90 days for this portfolio.

No PDUFA dates in the next 180 days for this portfolio.

No upcoming patent expiries for this portfolio.

No competitive overlap data.

Every new pipeline event for Syntara:

Drug Landscape (2026). Syntara — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/syntara. Accessed 2026-05-13.